{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:20:47Z","timestamp":1764307247905,"version":"3.46.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ischemic Heart Disease (IHD) represents one of the major causes of mortality and morbidity in the geriatric population This clinical complexity of these patients substantially impacts their quality of life and is associated with an increased risk of cognitive impairment (CoI). Ranolazine, plays a pivotal role in managing anginal symptoms and improving exercise tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the potential protective effect of Ranolazine on CoI over time in elderly patients with IHD and multiple comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a single-center, prospective, observational cohort study. The primary endpoint was a reduction in MMSE score \u22653 points during follow-up compared to baseline values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>519 patients with a mean age of 74.2 \u00b1 6.8\u00a0years were enrolled and divided into two groups based on Ranolazine use. The groups demonstrated comparable distribution by sex; however, Ranolazine group, although younger, displayed increased severity of anginal symptoms (Canadian Angina Scale 2.6 vs. 2.3; p &amp;lt; 0.0001), higher prevalence of previous acute coronary syndrome (p &amp;lt; 0.046), sarcopenia (p &amp;lt; 0.0001), and type 2 diabetes mellitus (p &amp;lt; 0.040). During a 4-year follow-up, 186 cases of CoI were observed (8.9 events\/100 patient-years) in the general population. The incidence of CoI was significantly lower in the Ranolazine group compared to the control group (5.7 vs. 10.3 events\/100 patient-years; p &amp;lt; 0.001). Multivariate analysis revealed a statistically significant association between CoI and the use of Ranolazine, GLP-1RAs, and SGLT2i. Specifically, Ranolazine use was associated with a 61% odds reduction in CoI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of Ranolazine is associated with a significant odds reduction in CoI in elderly patients with IHD and multiple comorbidities. The neuroprotective effect of Ranolazine may be attributed to the improvement of anginal symptoms and consequent optimization of functional status and quality of life, advocating for a comprehensive therapeutic strategy in geriatric patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1664988","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:15:58Z","timestamp":1764306958000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Giandomenico","family":"Severini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Armentaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Velia","family":"Cassano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentino","family":"Condoleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Alberto","family":"Pastura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Panza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Fuoco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Teresa","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Perticone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Succurro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Andreozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Sesti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Sciacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1016\/j.clinthera.2020.09.008","article-title":"Potential therapeutic effects of sodium glucose-linked cotransporter 2 inhibitors in stroke","volume":"42","author":"Al Hamed","year":"2020","journal-title":"Clin. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0150619","DOI":"10.1371\/journal.pone.0150619","article-title":"Effects of ranolazine on astrocytes and neurons in primary culture","volume":"11","author":"Aldasoro","year":"2016","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijcard.2015.10.180","article-title":"Ranolazine reduces angina frequency and severity and improves quality of life: observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR)","volume":"205","author":"Alexopoulos","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/jcm13071891","article-title":"The impact of geriatric conditions in elderly patients with coronary heart disease: a state-of-the-art review","volume":"13","author":"Alonso Salinas","year":"2024","journal-title":"J. Clin. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ejhf.3262","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with changes in comprehensive geriatric assessment in elderly diabetic patients with heart failure: data from MAGIC-HF","volume":"26","author":"Armentaro","year":"2024","journal-title":"Eur. J. Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","article-title":"Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?","volume":"118","author":"Bassil","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.tins.2024.04.004","article-title":"Physical exercise, cognition, and brain health in aging","volume":"47","author":"Boa Sorte Silva","year":"2024","journal-title":"Trends Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1161\/circ.54.3.947585","article-title":"Letter: grading of angina pectoris","volume":"54","author":"Campeau","year":"1976","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/nu12020382","article-title":"Metabolic and cognitive effects of ranolazine in type 2 diabetes mellitus: data from an in vivo model","volume":"12","author":"Cassano","year":"2020","journal-title":"Nutrients"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16160","DOI":"10.3390\/ijms232416160","article-title":"Ranolazine attenuates brain inflammation in a rat model of type 2 diabetes","volume":"23","author":"Cassano","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12035-012-8259-8","article-title":"Peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) and neurodegenerative disorders","volume":"46","author":"Chen","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/DDDT.S348055","article-title":"The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases","volume":"16","author":"Cheng","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"104818","DOI":"10.1016\/j.yexmp.2022.104818","article-title":"Ranolazine alleviated cardiac\/brain dysfunction in doxorubicin-treated rats","volume":"127","author":"Chunchai","year":"2022","journal-title":"Exp. Mol. Pathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1161\/CIRCULATIONAHA.124.068774","article-title":"Effect of sacubitril\/valsartan on cognitive function in patients with heart failure with preserved ejection fraction: a prespecified analysis of PARAGON-HF","volume":"150","author":"Dewan","year":"2024","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.mrfmmm.2009.08.016","article-title":"Activated astroglia during chronic inflammation in Alzheimer's disease--do they neglect their neurosupportive roles?","volume":"690","author":"Fuller","year":"2010","journal-title":"Mutat. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2174\/18715273113126660137","article-title":"Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation","volume":"13","author":"Kamal","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B18","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e9349","DOI":"10.7759\/cureus.9349","article-title":"Global epidemiology of ischemic heart disease: results from the global burden of disease study","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3390\/biomedicines12081750","article-title":"Impact of sodium glucose cotransporter 2 inhibitors (SGLT2i) therapy on dementia and cognitive decline","volume":"12","author":"Lardaro","year":"2024","journal-title":"Biomedicines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"B22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e02108","DOI":"10.1002\/brb3.2108","article-title":"Associations between coronary heart disease and risk of cognitive impairment: a meta-analysis","volume":"11","author":"Liang","year":"2021","journal-title":"Brain Behav."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/eurheartj\/ehz961","article-title":"Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease","volume":"41","author":"Liberale","year":"2020","journal-title":"Eur. Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.jacc.2017.12.068","article-title":"Coronary artery disease in patients 80 years of age","volume":"71","author":"Madhavan","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"8811","DOI":"10.3390\/ijms25168811","article-title":"Effects of SGLT2-inhibitors on comprehensive geriatric assessment, biomarkers of oxidative stress, and platelet activation in elderly diabetic patients with heart failure with preserved ejection fraction","volume":"25","author":"Magurno","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"102018","DOI":"10.1016\/j.arr.2023.102018","article-title":"Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways","volume":"90","author":"Mancinetti","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjms.2023.12.001","article-title":"Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes","volume":"367","author":"Manolis","year":"2024","journal-title":"Am. J. Med. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2022.11.009","article-title":"Ischemia and no obstructive coronary arteries (INOCA): a narrative review","volume":"363","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3390\/jcm13061672","article-title":"Real-world data from the use of ranolazine in patients with stable angina pectoris: the RANGER study","volume":"13","author":"Olympios","year":"2024","journal-title":"J. Clin. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"B36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.15420\/ecr.2018.26.1","article-title":"Stable angina medical therapy management guidelines: a critical review of guidelines from the european society of cardiology and national institute for health and care excellence","volume":"14","author":"Rousan","year":"2019","journal-title":"Eur. Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1267675","DOI":"10.3389\/fnins.2023.1267675","article-title":"Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia","volume":"17","author":"Samir","year":"2024","journal-title":"Front. Neurosci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1093\/eurheartj\/suaa060","article-title":"Treatment of stable ischaemic heart disease: the old and the new","volume":"22","author":"Santucci","year":"2020","journal-title":"Eur. Heart J. Suppl."},{"key":"B39","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/2047487312450133","article-title":"Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination assessment of ranolazine in stable angina (CARISA) randomized trial","volume":"19","author":"Send\u00f3n","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40266-025-01183-8","article-title":"Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in older adults with variable disease states: a meta-analysis of large placebo-controlled trials","volume":"42","author":"Shah","year":"2025","journal-title":"Drugs Aging"},{"key":"B41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2217\/fca-2021-0058","article-title":"Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina","volume":"18","author":"Tamargo","year":"2022","journal-title":"Future Cardiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fphar.2011.00054","article-title":"Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes","volume":"2","author":"Theile","year":"2011","journal-title":"Front. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur. Heart J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1017\/S1355617717000546","article-title":"Self-perceived difficulties in everyday function precede cognitive decline among older adults in the ACTIVE study","volume":"24","author":"Tomaszewski","year":"2018","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the european society of cardiology (ESC) endorsed by the european association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.amjcard.2019.05.063","article-title":"Effects of exercise training with and without ranolazine on peak oxygen consumption, daily physical activity, and quality of life in patients with chronic stable angina pectoris","volume":"124","author":"Willis","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"110656","DOI":"10.1016\/j.biopha.2020.110656","article-title":"Dysfunction of the neurovascular unit in diabetes-related neurodegeneration","volume":"131","author":"Yan","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"","journal-title":"J. Psychiatr. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.3390\/ijms24076039","article-title":"Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control","volume":"24","author":"Youssef","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00508-019-1481-x","article-title":"Ranolazine: impact on quality of life in patients with stable angina pectoris, results from an observational study in Austria - the ARETHA AT study","volume":"131","author":"Zweiker","year":"2019","journal-title":"Wien Klin. Wochenschr"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1664988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:15:59Z","timestamp":1764306959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1664988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":50,"alternative-id":["10.3389\/fphar.2025.1664988"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1664988","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"1664988"}}